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Resumo
A síndrome de Asperger é uma perturbação caraterizada pelo compromisso da interação social e um padrão de 
comportamentos estereotipados. Estes incluem comportamentos repetitivos, irritabilidade, agressividade, hiperatividade 
e desatenção. O tratamento dos sintomas comportamentais constitui um desafio, com escassos estudos acerca da 
eficácia das diferentes abordagens terapêuticas. Este artigo é a primeira descrição do uso bem ‑sucedido de palmitato de 
paliperidona mensal no tratamento de sintomas comportamentais num adulto com síndrome de Asperger.
Abstract
Asperger’s syndrome is a disorder characterized by impaired social interaction and a pattern of stereotyped behaviors. 
These include repetitive behaviors, irritability, aggressiveness, hyperactivity and inattention. The treatment of 
behavioral symptoms is a challenge, with few studies on the effectiveness of different therapeutic approaches. This 
article is the first description of the successful use of monthly paliperidone palmitate in the treatment of behavioral 
symptoms in an adult with Asperger’s syndrome.
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INTRODUCTION
Asperger’s syndrome (AS) is a subtype of pervasive devel‑
opment disorders in the ICD ‑10.1 It is characterized by an 
impairment in social interaction and a pattern of restricted 
or stereotyped behavior. 2 Patients show no language de‑
lay and their cognitive development is not marked by an 
overall delay but by specific impairments in certain areas 
such as the executive functions.3,4 Behavioral symptoms 
associated with AS include repetitive behaviors, irrita‑
bility, aggression, hyperactivity, inattention, and social 
impairment. Irritability in AS may include severe temper 
outbursts and/or impulsive aggression towards one ‑self or 
others. Moderate ‑to ‑severe irritability is known to occur in 
up to 30% of the patients with AS.3
Behavioral symptoms associated with AS are most com‑
monly treated with serotonin selective reuptake inhibitors 
(SSRIs), psychostimulants, and antipsychotics.2 SSRIs are 
less effective than antipsychotics and while psychostimu‑
lants demonstrate some benefit for the treatment of hyper‑
activity and inattention in individuals with AS, they are also 
associated with more adverse effects than antipsychotics.2 
Antipsychotics, namely aripiprazole and risperidone, are 
the most effective medications for the treatment of behav‑
ioral symptoms in AS.5 Oral paliperidone appears effective 
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for the treatment of irritability in children, adolescents, and 
adults with AS.6 ‑9 A trial of oral paliperidone conducted in 
adolescents and young adults with autism demonstrated an 
84% response rate in the treatment of irritability.10
In 2010, the European Medicines Agency approved a 
monthly sustained ‑release intramuscular (IM) formulation 
of the atypical antipsychotic paliperidone, paliperidone 
palmitate, for the treatment of adults with schizophrenia.11 
In this report, we report the first successful use of month‑
ly paliperidone palmitate for the treatment of behavioral 
symptoms in an adult with AS.
CASE REPORT
A 29 ‑year ‑old man diagnosed at the age of 4 with AS by 
a child and adolescent psychiatrist using ICD ‑10 criteria 
(F84.5). 1 At the age of 3, there were relevant delays in 
social interaction, as well as intense irritability including 
frequent severe tantrums and self ‑directed aggressive 
behavior, on the count of one every two days. He was 
administered thioridazine until the age of 9 with incom‑
plete behavior control, and thus a switch for risperidone 2 
mg daily was made. There was unremitting hyperactivity, 
psychomotor agitation, as well as moderate difficulties in 
reading and writing, and the dose was progressively in‑
creased towards 6 mg daily until he was around 14 years 
old. At this age, after 2 generalized tonic ‑clonic seizures 
he was diagnosed with epilepsy and started valproic acid 
1500 mg/day. For the next two years there were around 3 
to 4 seizures per month, and topiramate 300 mg/day was 
added. Due to incomplete seizure control, at 18 years old 
clobazam 10 mg/day was given on top of the other medica‑
tions, with complete epilepsy control. At the age of 20, the 
self and hetero ‑aggressive episodes, especially towards his 
mother, became more frequent and violent, with between 
two and three episodes per day. There were erotomaniac 
delusions regarding his female neighbors and sexualized 
behaviors towards strangers, and therefore risperidone was 
increased to 9 mg/day. Until the age of 27, tantrums of 
irritability, bingeing episodes, stereotyped motor behav‑
iors, coprolalia and echolalia were present. Amisulpride 
25 mg/day, escitalopram 5 mg/day and haloperidol 10 mg/
day were intermittently given on the top of the previous 
medications, with no significant improvement. His Patient 
Global Impression of Change Scale (PGIC ‑VP) score was 
2, despite full adherence to the medication, as stated by his 
mother, and verified by serum valproic acid levels regular‑
ly within the therapeutic range.12
At the age of 28, he was switched to oral paliperidone 6 
mg/day, while maintaining valproic acid, topiramate, and 
clobazam. All other medications were stopped. After 2 
weeks, his mother referred an improvement in his behav‑
ior and also in the intellectual depth of his conversations. 
There was no reappearance of motor symptoms, and he 
became responsible for his own medication. Because of 
the increased capacity in impulse control, namely in con‑
trolling food binges, there was a 5 kg weight lost. Due to 
the maintained gains in behavior control, five months later 
he was transitioned to the long ‑acting formulation, and did 
the induction scheme of 150 mg, plus 100 mg eight days 
later, followed by paliperidone palmitate 75 mg monthly. 
He was able to start voluntary work at a clinic, and for 
some of the weekdays he managed to live by himself at a 
family house next to the clinic. After 3 months of therapy 
with palmitate paliperidone had elapsed, the reemergence 
of irritably and motor stereotypies one week before the 
next administration was due were noticed, and thus he 
started taking palmitate paliperidone 100 mg monthly. He 
was also taking valproic acid 2000 mg/day, topiramate 
150 mg/day, and clobazam 10 mg/day. Twelve months 
have elapsed and, since he started palmitate paliperidone, 
improvements both in irritability and motor behavior have 
been maintained, with no episodes of self or hetero aggres‑
sion ever since. At present, his Patient Global Impression 
of Change Scale (PGIC ‑VP) score is 6.12
DISCUSSION
Paliperidone is the active metabolite of risperidone but 
is not metabolized extensively in the liver,13 thus having 
fewer pharmacokinetic interactions. It usually lacks the 
drowsiness, dizziness, lightheadedness, and confusion 
risperidone produces when administered with valproic 
acid, especially when administered by injection. Another 
advantage is that paliperidone is provided in a sustained‑
‑release formulation, even in the oral form, making it pos‑
sible to be administered once ‑daily and reducing the side 
effects related to the rapid absorption of risperidone. A 
lower equivalent ‑dose is thus also possible, in comparison 
with other antipsychotics (e.g. haloperidol, risperidone, 
etc.).14 ‑16
This case reports the successful use of paliperidone in its 
oral formulation, and maintenance of the remission of 
behavioral symptoms with an equivalent dose of its long‑
‑acting injectable formulation in an adult with AS. The 
three ‑monthly paliperidone palmitate will probably also 
be successful in AS.
To the best of our knowledge, it is the first described case 
of paliperidone palmitate in an adult with AS and the re‑
sults are compelling.
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